The following video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson and industrials editor/analyst Isaac Pino discuss topics across the investing world.
In this video, David and Isaac discuss two biotechs that have recently seen shares soar. Regeneron has been on a tear and seemingly can't raise Eylea guidance fast enough. Amarin is well off 52-week highs, but bad news for a competitor is good news for Amarin. Can both stocks keep the runs going, or should investors stay on the sidelines post-pop? Watch and find out.
Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report: "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.